🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05160987
Recruiting Not applicable

Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam

NCT05160987 · tracked via the Priya Life Science China tracker
Sponsor
Zhujiang Hospital
Phase
Not applicable
Started
2022-03-29
Last updated
2026-04-17

Condition(s) studied

Sedation and Analgesia

Investigational drug(s) / intervention(s)

Remimazolam →Midazolam →

Remimazolam: Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.

Midazolam: Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.

Study summary

In this parallel, multicenter, single-blind randomized controlled trial, mechanical ventilated patients will be randomly assigned to two groups. One receives remimazolam to achieve sedation goals, while the other receives Midazolam. The primary outcome is the effect of remimazolam on duration of mechanical ventilated of critical patients compared to midazolam.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Critical ill patients that are mechanically ventilated within the first 48h of admission to the ICU and who would remain in the ICU for over 72h were enrolled in this study. 2. Age 18-80 years. 3. Voluntary informed consent. Exclusion Criteria: 1. Surgical treatment is performed within 24 hours. 2. Craniocerebral injury, post neurosurgery, non drug coma, mental illness or peripheral neuropathy. 3. Heart rates are less than 50 beats / min or severe atrioventricular block without pacemaker support. 4. The mean arterial pressure is less than 55 mmHg even though fluids and vasoactive drugs are administrated. 5. Patients who are known or suspected allergy to benzodiazepines, propofol, dexmedetomidine or opioids. 6. History of alcohol and drug abuse. 7. End stages of lung diseases, such as pulmonary fibrosis, lung damage, etc. 8. Pregnancy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University Guangzhou Guangdong Recruiting

More Zhujiang Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05160987 on ClinicalTrials.gov ↗ ← All trials in China